MX2020003001A - Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. - Google Patents
Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.Info
- Publication number
- MX2020003001A MX2020003001A MX2020003001A MX2020003001A MX2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A
- Authority
- MX
- Mexico
- Prior art keywords
- water
- roflumilast
- miscible
- pharmaceutically acceptable
- pharmaceutical compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002904 solvent Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical group FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002586 roflumilast Drugs 0.000 title abstract 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La baja solubilidad acuosa de roflumilast en preparaciones parenterales y emulsiones tópicas, suspensiones, geles o soluciones se puede mejorar al incluir una mezcla de solventes miscibles en agua en la composición farmacéutica; la mezcla de solventes miscibles en agua puede incluir dietilen glicol monoetil éter (Nombre comercial Transcutol(r); abreviado DEGEE) y agua; la relación de dietilen glicol monoetil éter a agua es de 1:10 a 20:1; la composición resultante tiene biodisponibilidad y eficacia mejoradas y se puede utilizar para inhibir la fosfodiesterasa 4 en un paciente en necesidad de dicho tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/712,900 US11534493B2 (en) | 2017-09-22 | 2017-09-22 | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
PCT/US2018/051691 WO2019060379A1 (en) | 2017-09-22 | 2018-09-19 | PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS MIXTURES OF PHARMACEUTICALLY ACCEPTABLE SOLVENTS MISCIBLE TO WATER |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003001A true MX2020003001A (es) | 2020-09-28 |
Family
ID=63794682
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003001A MX2020003001A (es) | 2017-09-22 | 2018-09-19 | Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. |
MX2023011557A MX2023011557A (es) | 2017-09-22 | 2020-03-18 | Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023011557A MX2023011557A (es) | 2017-09-22 | 2020-03-18 | Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11534493B2 (es) |
EP (2) | EP3684334B1 (es) |
JP (3) | JP7191944B2 (es) |
KR (1) | KR102681877B1 (es) |
CN (1) | CN111107836A (es) |
AU (1) | AU2018337752B2 (es) |
BR (1) | BR112020005421A8 (es) |
CA (1) | CA3076002A1 (es) |
EA (1) | EA202090813A1 (es) |
ES (1) | ES2972843T3 (es) |
IL (1) | IL273376B2 (es) |
MX (2) | MX2020003001A (es) |
WO (1) | WO2019060379A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
US9895359B1 (en) * | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
KR20210044191A (ko) | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | 로플루밀라스트 피부 침투 지연 시간의 개선 방법 및 제형 |
CN114828840A (zh) * | 2019-10-11 | 2022-07-29 | 泽威恩制药有限责任公司 | 秋水仙碱的改进的局部用组合物 |
MX2022009399A (es) * | 2020-01-31 | 2022-09-19 | Arcutis Biotherapeutics Inc | Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica. |
WO2022169615A1 (en) * | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2259692A (en) * | 1991-07-03 | 1993-02-11 | Sano Corporation | Composition and method for transdermal delivery of diclofenac |
KR100331255B1 (ko) | 1993-07-02 | 2002-10-25 | 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 | 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도 |
GB9618974D0 (en) * | 1996-09-11 | 1996-10-23 | Glaxo Group Ltd | Medicaments |
FR2758459B1 (fr) | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
UA80393C2 (uk) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
CN101491520B (zh) | 2002-05-28 | 2011-03-16 | 尼科梅德有限责任公司 | 局部应用的药物制剂 |
MXPA04008070A (es) | 2003-03-10 | 2004-11-26 | Altana Pharma Ag | Novedoso proceso para la preparacion de roflumilasto. |
US20060204526A1 (en) * | 2003-08-13 | 2006-09-14 | Lathrop Robert W | Emulsive composition containing Dapsone |
MXPA06003316A (es) * | 2003-10-10 | 2006-06-08 | Antares Pharma Ipl Ag | Formulacion farmaceutica transdermica para minimizar los residuos en la piel. |
DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
WO2006041121A1 (ja) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | 慢性皮膚疾患の治療および/または予防剤 |
FR2898499B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
WO2007127158A2 (en) * | 2006-04-25 | 2007-11-08 | Croda, Inc | Modification of percutaneous absorption of topically active materials |
CN101541321A (zh) * | 2006-09-06 | 2009-09-23 | Isw集团公司 | 局部用组合物 |
US7893097B2 (en) * | 2008-02-02 | 2011-02-22 | Dow Pharmaceutical Sciences, Inc. | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water |
US20110117182A1 (en) * | 2009-07-30 | 2011-05-19 | Allergan, Inc. | Combination of dapsone with other anti-acne agents |
US20120252793A1 (en) | 2011-03-31 | 2012-10-04 | Gary Bream | Intranasal benzodiazepine pharmaceutical compositions |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
DK2704703T3 (da) * | 2011-05-03 | 2019-10-14 | Aponia Laboratories Inc | Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf |
WO2013030789A1 (en) | 2011-08-30 | 2013-03-07 | Ranbaxy Laboratories Limited | Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor |
EP2903619B1 (en) | 2012-10-05 | 2019-06-05 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
EP3763366A1 (en) | 2013-01-28 | 2021-01-13 | Incozen Therapeutics Pvt. Ltd. | Roflumilast n-oxide for use in treating autoimmune, respiratory and inflammatory disorders by inhalation |
US20140275265A1 (en) * | 2013-03-12 | 2014-09-18 | Core Products International, Inc. | Therapeutic cream for application to skin |
UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
WO2015132708A1 (en) | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
BR112017004032A2 (pt) * | 2014-08-27 | 2017-12-05 | Abbvie Inc | formulação tópica |
KR102106230B1 (ko) | 2015-11-30 | 2020-04-29 | 아나코르 파마슈티칼스 인코포레이티드 | 염증성-관련 상태를 치료하기 위한 국소 제약 제제 |
CN109310624A (zh) * | 2016-06-15 | 2019-02-05 | 托伦特药物有限公司 | 阿普斯特的局部组合物 |
US9895359B1 (en) * | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
-
2017
- 2017-09-22 US US15/712,900 patent/US11534493B2/en active Active
-
2018
- 2018-09-19 MX MX2020003001A patent/MX2020003001A/es unknown
- 2018-09-19 JP JP2020516414A patent/JP7191944B2/ja active Active
- 2018-09-19 IL IL273376A patent/IL273376B2/en unknown
- 2018-09-19 EP EP18783250.6A patent/EP3684334B1/en active Active
- 2018-09-19 BR BR112020005421A patent/BR112020005421A8/pt active Search and Examination
- 2018-09-19 EA EA202090813A patent/EA202090813A1/ru unknown
- 2018-09-19 AU AU2018337752A patent/AU2018337752B2/en active Active
- 2018-09-19 CA CA3076002A patent/CA3076002A1/en active Pending
- 2018-09-19 ES ES18783250T patent/ES2972843T3/es active Active
- 2018-09-19 WO PCT/US2018/051691 patent/WO2019060379A1/en unknown
- 2018-09-19 KR KR1020207008018A patent/KR102681877B1/ko active IP Right Grant
- 2018-09-19 EP EP23214185.3A patent/EP4316590A3/en active Pending
- 2018-09-19 CN CN201880060842.2A patent/CN111107836A/zh active Pending
-
2020
- 2020-03-18 MX MX2023011557A patent/MX2023011557A/es unknown
-
2022
- 2022-11-22 US US18/057,777 patent/US20230091358A1/en active Pending
- 2022-12-07 JP JP2022195731A patent/JP7402301B2/ja active Active
-
2023
- 2023-12-07 JP JP2023207175A patent/JP2024028911A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA202090813A1 (ru) | 2020-08-14 |
IL273376B2 (en) | 2024-07-01 |
IL273376B1 (en) | 2024-03-01 |
US20230091358A1 (en) | 2023-03-23 |
US20190091333A1 (en) | 2019-03-28 |
WO2019060379A1 (en) | 2019-03-28 |
JP2024028911A (ja) | 2024-03-05 |
EP4316590A3 (en) | 2024-05-01 |
EP3684334C0 (en) | 2023-12-06 |
AU2018337752B2 (en) | 2024-03-28 |
JP2020534303A (ja) | 2020-11-26 |
MX2023011557A (es) | 2023-10-09 |
EP3684334A1 (en) | 2020-07-29 |
ES2972843T3 (es) | 2024-06-17 |
EP4316590A2 (en) | 2024-02-07 |
CA3076002A1 (en) | 2019-03-28 |
KR102681877B1 (ko) | 2024-07-04 |
JP7402301B2 (ja) | 2023-12-20 |
CN111107836A (zh) | 2020-05-05 |
JP7191944B2 (ja) | 2022-12-19 |
JP2023027195A (ja) | 2023-03-01 |
EP3684334B1 (en) | 2023-12-06 |
US11534493B2 (en) | 2022-12-27 |
BR112020005421A2 (pt) | 2020-09-29 |
IL273376A (en) | 2020-05-31 |
AU2018337752A1 (en) | 2020-04-09 |
KR20200058402A (ko) | 2020-05-27 |
BR112020005421A8 (pt) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023011557A (es) | Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables. | |
EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
MX2022013596A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
MY197785A (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
WO2015120231A3 (en) | Stable peptide formulations and methods for preparation | |
EA201600118A1 (ru) | Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина | |
TN2015000445A1 (en) | Derivatives of dolastatin 10 and auristatins | |
MY179605A (en) | Use of benzimidazole-proline derivatives | |
MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
MX2013007909A (es) | Formulaciones inmunosupresoras. | |
ZA202103090B (en) | Pharmaceutical formulations of cyclosporine analogs | |
EA201690077A1 (ru) | Терапевтически активные производные эстратриен-тиазола | |
SA521430973B1 (ar) | صيغ علاجية ثابتة في مذيبات قطبية غير بروتونية وطرق لتصنيعها | |
EA202090445A1 (ru) | ПРОТИВОГРИБКОВЫЕ СРЕДСТВА С ПОВЫШЕННОЙ АКТИВНОСТЬЮ ПРИ КИСЛОМ pH | |
EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
SA520412443B1 (ar) | تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول | |
MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
MY198473A (en) | Glucono delta-lactone for treatment of vaginal fungal infections | |
MX2019004576A (es) | Composiciones farmaceuticas. | |
RU2017129736A (ru) | Не окрашивающая гелевая композиция, содержащая нимесулид, для местного применения | |
WO2019166033A3 (zh) | 维生素c偶联铂配合物、其中间体、其制备方法、药物组合物及用途 | |
MX2019010618A (es) | Composicion farmacéutica oftálmica, procesos de preparación y usos de las mismas. | |
MX2021000403A (es) | Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma. |